Searchable abstracts of presentations at key conferences in endocrinology

ea0037gp.02.07 | Adrenal (1) | ECE2015

Urinary free cortisone as a potential biomarker in diagnosing patients with mild Cushing's syndrome

Trementino Laura , Concettoni Carolina , Martino Marianna , Marcelli Giorgia , Michetti Grazia , Boscaro Marco , Arnaldi Giorgio

Introduction: Urinary free cortisol (UFC) determination has suboptimal sensitivity (SE) and specificity (SP) especially in mild Cushing’s syndrome (CS).Aim: To determine the performance of UFC and its metabolite cortisone (UFE) measured using accurate assays such as HPLC and LC–MS/MS in diagnosing patients with CS.Patients and methods: Sixty-seven patients with CS were compared to 49 sex- and age-matched non-CS. UFF and U...

ea0035p19 | Adrenal cortex | ECE2014

Acute pasireotide suppression test in patients with Cushing's disease: a role in predicting long-term efficacy?

Trementino Laura , Marcelli Giorgia , Michetti Grazia , Concettoni Carolina , Boscaro Marco , Arnaldi Giorgio

Introduction: Pasireotide is a multireceptor-targeted somatostatin analogue effective in the treatment of patients with Cushing’s disease (CD) but associated with an increased risk of hyperglycaemia. We prospectively investigate the role of an acute pasireotide suppression test (PST) in predicting long-term response in CD.Methods: Eleven patients with CD (seven females, four males; mean age 45±17.3 years) received at 0900 h a single s.c. inject...

ea0035p46 | Adrenal cortex | ECE2014

Diagnostic performance of late-night salivary cortisol measured by automated chemiluminescenze immunoassay

Marcelli Giorgia , Brugia Marina , Concettoni Carolina , Trementino Laura , Michetti Grazia , Boscaro Marco , Arnaldi Giorgio

Context: Late-night salivary cortisol (LNSC) measurement has been promoted as an ideal screening test for the diagnosis of Cushing’s syndrome (CS). However, its performance using commercially available assays has not been widely evaluated and limited data are available on its use in population with chronic medical conditions.Aim: To compare the diagnostic performance of LNSC (routine use) in patients with CS and in a patients’s group with diffe...

ea0032p33 | Adrenal cortex | ECE2013

Salivary cortisol is a useful tool to assess the immediate response to pasireotide in patients with Cushing’s disease

Cardinaletti Marina , Trementino Laura , Concettoni Carolina , Marcelli Giorgia , Polenta Barbara , Spinello Maurizio , Boscaro Marco , Arnaldi Giorgio

Introduction: Pasireotide is a promising treatment option for patients with Cushing’s disease (CD). The measurement of salivary cortisol is useful for diagnosing hypercortisolism and monitoring patients with CD following pituitary surgery. It may also be a better index of cortisol secretion than serum cortisol or urinary free cortisol (UFC). We investigated the value of salivary cortisol in monitoring short-term efficacy of pasireotide in patients with CD.<p class="ab...

ea0032p45 | Adrenal cortex | ECE2013

Long-term efficacy of pasireotide in a patient with Cushing's disease and diabetes: results in the short term are not always predictive of long-term response

Trementino Laura , Cardinaletti Marina , Concettoni Carolina , Marcelli Giorgia , Boscaro Marco , Arnaldi Giorgio

The management of Cushing’s disease (CD) can be problematic, particularly when the disease persists following pituitary surgery. Here we report the case of a 55-year old woman with CD that persisted after repeat transsphenoidal surgery. The patient had an overt phenotype with facial rubeosis, central obesity with supraclavicular fat accumulation, cervical fat pad and proximal muscle weakness. She had received anti-hypertensive drugs and insulin for diabetes mellitus. Horm...

ea0016p26 | Adrenal | ECE2008

Glucocorticoid receptor gene polymorphisms and bone mineral density in hpa axis disorders

Arnaldi Giorgio , Appolloni Gloria , Romagni Paola , Cardinaletti Marina , Trementino Laura , Polenta Barbara , Concettoni Carolina , Boscaro Marco

Glucocorticoid receptor (GR) gene polymorphisms have been associated with interindividual variations in glucocorticoid sensitivity in healthy individuals.Aim: Aim of this study was to investigate whether there was an association with sensitivity to glucocorticoids and bone mineral density in HPA axis disorders.Methods: We analyzed 3 polymorphisms of the GR gene (Bcl1, N363S, ER22/23EK) in 185 subjects: 52 patients with Cushing&#146...

ea0016p125 | Clinical cases | ECE2008

Effects of gender on clinical and biochemical features in Cushing's disease

Cardinaletti Marina , Trementino Laura , Polenta Barbara , Concettoni Carolina , Mancini Tatiana , Boscaro Marco , Arnaldi Giorgio

Cushing’s disease (CD) occur more frequently in females than in males, but in men this disease seems appear at a younger age and with more severe symptoms and clinical course. Aim of this study was to compare clinical features and biochemical indices of hypercortisolism in male and female patients with CD.Methods: Forty-five patients (35 females and 10 males) with confirmed CD were analyzed. All patients underwent a complete biochemical and endocrin...

ea0056p58 | Adrenal cortex (to include Cushing's) | ECE2018

The diagnostic accuracy of increased late night salivary cortisol for Cushing’s Syndrome: a real-life prospective study

Ceccato Filippo , Marcelli Giorgia , Martino Marianna , Concettoni Carolina , Brugia Marina , Trementino Laura , Michetti Grazia , Arnaldi Giorgio

Introduction and aim: A prompt diagnosis of Cushing’s Syndrome (CS) in high-risk populations is mandatory: 1-mg dexamethasone suppression test (1-mg DST); late night salivary cortisol (LNSC) and urinary free cortisol (UFC) are recommend, despite thresholds calculated in retrospective studies. Our aim was to study the diagnostic accuracy of LNSC measured with chemiluminescence assay in a prospective study, confirming discrepancies with mass spectrometry (MS).<p class="...

ea0037ep88 | Adrenal cortex | ECE2015

A single-centre 10-years experience with pasireotide in Cushing's disease: patients characteristics and outcome

Trementino Laura , Michetti Grazia , Angeletti Alessia , Marcelli Giorgia , Concettoni Carolina , Cardinaletti Marina , Polenta Barbara , Boscaro Marco , Arnaldi Giorgio

Introduction: Pasireotide is the first pituitary-directed drug approved for Cushing’s disease (CD). We report our 10-years experience with pasireotide in CD reviewing and analysing data about all the patients treated with pasireotide at our referral centre both in randomised trials and in clinical practice.Patients and methods: Twenty active CD patients were treated. Fourteen patients were treated with pasireotide in randomised trials and six patien...